(lp0
S'CytRx Granted Type B Pre-NDA Meeting with US FDA for Registration Pathway with ... PR Newswire  - Jan 4, 2017 LOS ANGELES, Jan. 4, 2017 /PRNewswire/ -- CytRx Corporation , a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, today announced that,&nbsp;...'
p1
aS'CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common ... PR Newswire  - Dec 13, 2016 LOS ANGELES, Dec. 13, 2016 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into securities purchase agreements with existing&nbsp;...'
p2
aS"CytRx to Present at the 29th Annual ROTH Conference PR Newswire  - Mar 7, 2017 LOS ANGELES, March 7, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice&nbsp;...CytRx Corporation  traded with Volume of 1.28 Million shares in ... - The Newburgh PressCytRx Corporation's  stock price is Worth at $0.42 - Hot Stocks Point"
p3
aS'CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer PR Newswire  - Dec 19, 2016 LOS ANGELES, Dec. 19, 2016 /PRNewswire/ -- CytRx Corporation , a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, has appointed Daniel&nbsp;...'
p4
aS"Analyst Advice And Earnings Insight: CytRx Corporation , Kirby ... Post Analyst - 13 hours ago So far, analysts are sticking with their neutral recommendations with the consensus call at 2.9. Kirby Corporation has 1 buy ratings, 8 holds and 0 sells even after the stock tumbled -7.56% from its high of $73.4 to a $3.66 billion market value through ...Analyst's Indicator Review for CytRx Corporation , The Timken Company  - The USA CommerceCytRx Corporation's  share price has value at $0.41 with final change of ... - Street Updates"
p5
aS'CytRx: The BASIC Chemistry Seeking Alpha - Oct 26, 2016 This article is meant to explain the general science of CytRx  and why they will continue to fail. We go over basic chemistry of &quot;pH sensitive linkers&quot; - the fundamental platform of CytRx. Further, we want to make it clear that although ...'
p6
aS'CytRx Corporation  Soars 5.15% on March 20 Equities.com - Mar 20, 2017 CytRx Corporation  had a good day on the market for Monday March 20 as shares jumped 5.15% to close at $0.42. About 825,181 shares traded hands on 1,703 trades for the day, compared with an average daily volume of 1.37 million shares out of a&nbsp;...In focus: CytRx Corporation  Trading Patterns - Post AnalystCytRx Corporation  Quarterly EPS At $-0.11 - Stock Observer'
p7
aS'CytRx to Present at the 19th Annual BIO CEO &amp; Investor Conference PR Newswire  - Feb 6, 2017 LOS ANGELES, Feb. 6, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice&nbsp;...'
p8
aS'CytRx Corporation  Is A Top Contrarian Play Insider Financial - Oct 14, 2016 CytRx Corporation  has been the subject of some serious hit pieces over the last couple of months, on the back of the company announcing what was construed as disappointing results from an ongoing trial of its lead candidate,&nbsp;...'
p9
aS'CytRx Corporation  Plunges 5.35% on February 23 Equities.com - Feb 23, 2017 CytRx Corporation  had a rough trading day for Thursday February 23 as shares tumbled 5.35%, or a loss of $-0.0241 per share, to close at $0.43.SABBY MANAGEMENT, LLC is the biggest holder of CytRx Corporation  - Post Analyst'
p10
a.